Analysis of Selected Clinical and Laboratory Parameters in Patients with Splenectomy Complications Due to Hematological Disorders

• Authors: Piotr Żukrowski , Wojciech Kielan , Zygmunt Grzebieniak , Jerzy Rudnicki , Robert Tarnawa , Anil Agrawal , Tomasz Bąk , Monika Knakiewicz
• Languages of publication: EN

Abstracts

EN

The aim of the study was to investigate the role of certain clinical characteristics and laboratory examination results as prognostic factors for complications after splenectomy in patients with hematological disorders.Material and methods. Ninety-eight adult patients with hematological disorders who underwent splenectomy in our department between years of 1994 and 2004. A retrospective analysis of the medical records from patients who underwent splenectomy was conducted; we divided the patients into 6 groups with various postoperative complications; patients without complications after splenectomy were the control group (the seventh group). Then, we compared patients from groups 1 - 6 with patients from the control group (group 7) before and after splenectomy with regard to various parameters including age, sex, presence of splenomegaly or accessory spleen, the operation's duration, hemoglobin level, number of erythrocytes, leukocytes and plateletes, levels of protein and fibrinogen, activity of prothrombin, INR, APTT, TT, proteinogram and levels of IgG, IgM and IgA.Results. We found that postoperative complications, especially early complications, were more common in groups with malignant hematological complications and in older patients. Infection complications appear more often in men than in women with benign hematological disorders. The sustained platelet level elevation after splenectomy is positively associated with a higher number of thrombotic complications. Also, a lower level of gamma globulin, IgG and IgM after splenectomy correlated with a higher number of infection complications.Conclusions. Splenectomy in patients with hematological disorders is burdened with small risks of postoperative complications. Some clinical and laboratory parameters can be used to select the group of patients with higher risks of complications, but there remains a lack of objective prognostic factors which are sure in every clinical situation.

Keywords

EN

splenectomy; hematological diseases; splenectomy complications

• Publisher: Index Copernicus International
• Journal: Polish Journal of Surgery
• Year: 2007
• Volume: 79
• Issue: 6
• Pages: 418-425

Dates

published

1 - 6 - 2007

online

27 - 11 - 2007

Contributors

author

Piotr Żukrowski

• 2nd Department of General and Oncological Surgery, Medical University in Wrocław

author

Wojciech Kielan

• 2nd Department of General and Oncological Surgery, Medical University in Wrocław

author

Zygmunt Grzebieniak

• 2nd Department of General and Oncological Surgery, Medical University in Wrocław

author

Jerzy Rudnicki

• 2nd Department of General and Oncological Surgery, Medical University in Wrocław

author

Robert Tarnawa

• 2nd Department of General and Oncological Surgery, Medical University in Wrocław

author

Anil Agrawal

author

Tomasz Bąk

• 2nd Department of General and Oncological Surgery, Medical University in Wrocław

author

Monika Knakiewicz

• 2nd Department of General and Oncological Surgery, Medical University in Wrocław

References

• Kojouri K, Vesely SK, Terrel DR et al.: Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess longterm platelet count responses, prediction of response, and surgical complications. Blood 2004; 104: 2623-34.
• Lockwood CM: Immunological functions of the spleen. Clin Haematol 1983; 12: 449-65.[PubMed]
• Hansen K, Singer DB: Asplenic-hyposplenic overwhelming sepsis: postsplenectomy sepsis revisited. Pediatr Dev Pathol 2001; 4: 105-21.
• Marques RG, Petroianu A: Overwhelming postsplenectomy infection. Arq Gastroenterol 2003; 40: 47-54.
• Pugliese R, Maggioni D, Scandroglio I et al.: Splenectomy in haematologic diseases. Clinical indications and surgical technique. Chir Ital 2005; 57: 283-91.
• Kumar S, Diehn FE, Gertz MA et al.: Splenectomy for immune thrombocytopenic purpura: longterm results and treatment of postsplenectomy relapses. Ann Hematol 2002; 81: 312-19.
• Tefferi A, Mesa RA, Nagorney DM et al.: Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000; 95: 2226-33.
• Akpek G, McAneny D, Weintraub L: Risks and benefits of splenectomy in myelofibrosis with myeloid metaplasia: a retrospective analysis of 26 cases. J Surg Oncol 2001; 77(1): 42-48.[PubMed][Crossref]
• Mesa RA, Tefferi A: Surgical and radiotherapeutic approaches for myelofibrosis with myeloid metaplasia. Semin Oncol 2005; 32(4): 403-13.[PubMed][Crossref]
• Pedersen FK: Postsplenectomy infections in Danish children splenectomized 1969-1978. Acta Paediatr Scand 1983; 72: 589-95.
• Deodhar HA, Marshall RJ, Barnes JN: Increased risk of sepsis after splenectomy. BMJ 1993; 307: 1408-09.
• Bisharat N, Omari H, Lavi et al.: R Risk of infection and death among post-splenectomy patients. J Infect 2001; 43(3): 182-86.[Crossref]
• Bader-Meunier B, Gauthier F, Archambaud F et al.: Long-term evaluation of the beneficial effect of subtotal splenectomy for management of hereditary spherocytosis. Blood 2001; 97: 399-403.
• Petroianu A, Resende V, Silva RG: Late postoperative follow-up of patients undergoing subtotal splenectomy. Clinics 2005; 60: 473-78.
• Stoehr GA, Stauffer UG, Eber SW: Near-total splenectomy: a new technique for the management of hereditary spherocytosis. Ann Surg 2005; 241: 40-47.
• Hołowiecka A, Zielińska M, Krzemień S, Hołowiecki J: Nawrót małopłytkowości u chorej z ITP po 18 latach od wykonania splenektomii. Acte Haematologica Polonica 2002; 33: 381-85.
• Stanek A, Stefaniak T, Makarewicz W et al.: Accessory spleens: preoperative diagnostics limitations and operational strategy in laparoscopic approach to splenectomy in idiopathic thrombocytopenic purpura patients. Langenbecks Arch Surg 2005; 390: 47-51.
• Walters DN, Roberts JL, Votaw M: Accessory splenectomy in the management of recurrent immune thrombocytopenic purpura. Am Surg 1998; 64: 1077-78.
• Scharf R, Ziemski JM: Chirurgia śledziony. (w:) Podstawy chirurgii. Szmidt J. (red.). Medycyna Praktyczna, Kraków 2004, 1025-39.
• Dingli D, Mesa RA, Tefferi A: Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment. Intern Med 2004; 43(7): 540-47.[PubMed][Crossref]
• Pietrabissa A, Moretto C, Antonelli G et al.: Thrombosis in the portal venous system after elective laparoscopic splenectomy. Surg Endosc 2004; 18(7): 1140-43.
• Plow EF, Abrams CS: The molecular basis for platelet function. W: Hematology : basic principles and practice. Hoffman R (red.). Elsevier Churchill Livingstone, Philadelphia 2005, 1881-1915.
• Hoffman R, Ravandi-Kashani F: Idiopathic Myelofibrosis. W: Hematology: basic principles and practice. Hoffman R (red.). Elsevier Churchill Livingstone, Philadelphia 2005, 1255-76.
• Ellis EF, Smith RT: The role of the spleen in immunity. With special reference to the post-splenectomy problem in infants. Pediatrics 1966; 37: 111-19.
• Kraus MD: Splenic histology and histopathology; an update. Semin Diagn Pathol 2003; 20(2): 84-93.[Crossref][PubMed]
• Kraus MD, Fleming MD, Vonderheide RH: The spleen as a diagnostic specimen: a review of 10 years' experience at two tertiary care institutions. Cancer 2001; 91(11): 2001-09.
• Chrobak L: Splenomegaly (clinical importance, diagnosis and therapy). Vnitr Lek 2002; 48(4): 325-31.[PubMed]
• Hansen K, Singer DB: Asplenic-hyposplenic overwhelming sepsis: postsplenectomy sepsis revisited. Pediatr Dev Pathol 2001; 4(2): 105-21.[PubMed][Crossref]
• Wronecki K: Wpływ splenektomii na wybrane wskaźniki immunologiczne u dzieci i na przebieg doświadczalnego zakażenia bakteryjnego u szczurów z uwzględnieniem roli tutftsinu. Wyd. Akademii Medycznej we Wrocławiu, Wrocław 1992.
• Yuste J, Botto M, Paton JC et al.: Additive inhibition of complement deposition by pneumolysin and PspA facilitates Stréptococcus pneumoniae septicemia. J Immunol 2005; 175(3): 1813-19.
• Jirillo E, Mastronardi ML, Altamura M et al.: The immunocompromised host: immune alterations in splenectomized patients and clinical implications. Curr Pharm Des 2003; 9(24): 1918-23.[Crossref]
• Altamura M, Cardonna L, Amati L et al.: Splenectomy and sepsis: the role of the spleen in the immune-mediated bacterial clearance. Immunopharmacol Immunotoxicol 2001; 23(2): 153-61.[Crossref]

Identifiers

DOI

10.2478/v10035-007-0065-z